TherapeuticsMD
TXMD
114 hedge funds and large institutions have $716M invested in TherapeuticsMD in 2015 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 50 increasing their positions, 36 reducing their positions, and 15 closing their positions.
506% more call options, than puts
Call options by funds: $19.8M | Put options by funds: $3.27M
39% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 36
0.11% more ownership
Funds ownership: 1.27% → 1.38% (+0.11%)
0% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 15
1% less funds holding
Funds holding: 115 → 114 (-1)
17% less capital invested
Capital invested by funds: $859M → $716M (-$143M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$34.8M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$20.3M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$17M |
| 4 |
Bank of New York Mellon
New York
|
+$6.9M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.69M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$11.6M |
| 2 |
Millennium Management
New York
|
-$4.32M |
| 3 |
BCM
Barometer Capital Management
Toronto,
Ontario, Canada
|
-$3.34M |
| 4 |
Morgan Stanley
New York
|
-$2.88M |
| 5 |
GTC
Ghost Tree Capital
New York
|
-$2.84M |
TXMD Hedge Fund Activity: Q3 2015 in Review
114 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in TherapeuticsMD (TXMD) for Q3 2015, worth a combined $716M — down 17% from $859M a quarter earlier.
Fund positioning in TXMD was balanced in Q3 2015: 15 funds opened new positions, 15 closed out, 50 added to existing stakes and 36 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $34.8M. The largest seller was Tekla Capital Management, exiting entirely with an estimated $11.6M sold.
- 114 institutional investors held TherapeuticsMD (TXMD) as of Q3 2015, down from 115 in Q2 2015.
- Funds reported $716M of TherapeuticsMD stock for Q3 2015, down 17% quarter-over-quarter.
- 15 funds opened new TherapeuticsMD positions in Q3 2015 and 15 closed out, a net change of 0 holders.
- The largest TherapeuticsMD buyer in Q3 2015 was JP Morgan Chase, an estimated $34.8M added.
- The largest TherapeuticsMD seller in Q3 2015 was Tekla Capital Management, an estimated $11.6M sold.
Based on aggregated 13F filings for Q3 2015.